OncoLize develops polymer-based hydrogel drug depots for localized and slow delivery of chemotherapy directly into tumors, specifically targeting pancreatic and aggressive cancers. This approach enhances drug concentration at the tumor site, improving treatment efficacy while minimizing systemic side effects and costs.
Funding
$1.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Systemic chemotherapy for pancreatic and aggressive cancers often results in severe side effects and limited efficacy due to non-specific drug distribution and inability to achieve sufficient drug concentrations within the tumor microenvironment. This leads to suboptimal tumor eradication and reduced patient survival rates.
Solution
OncoLize is developing polymer-based hydrogel drug depots designed for localized, slow-release delivery of chemotherapeutic agents directly into solid tumors. This targeted approach aims to increase drug concentration within the tumor while minimizing systemic exposure, thereby improving treatment efficacy and reducing adverse side effects. The hydrogel technology simplifies formulation development, enables scalable manufacturing, and ensures affordability. By concentrating the drug at the tumor site, OncoLize's approach seeks to enhance tumor eradication and improve patient outcomes.
Target Audience
The primary target audience includes oncologists and hospitals treating patients with pancreatic and other aggressive solid tumors, as well as pharmaceutical companies seeking innovative drug delivery technologies.
Features
- Polymer-based hydrogel for sustained drug release directly within the tumor
- Localized drug delivery to maximize efficacy and minimize systemic toxicity
- ChemGemTM platform for targeted delivery of Gemcitabine
- Scalable and affordable manufacturing process
- Applicability to various solid tumor types, including pancreatic cancer
- Granted patents in the USA, China, and Japan covering the ChemoGellTM platform